NGL Fine Chem Q4 PAT surges 2,400% to ₹13.5 Cr as margins double to 14.34%

Market snapshot: NGL Fine Chem has delivered a robust set of numbers for the fourth quarter of FY26, showcasing significant operational turnaround. The company reported a massive 24x jump in consolidated net profit compared to the previous year, driven by strong revenue growth and sharp margin expansion in the veterinary API segment.

Data Snapshot

• Revenue: ₹150 crore vs ₹95 crore (YoY)
• EBITDA: ₹21.4 crore vs ₹6.3 crore (YoY)
• Net Profit: ₹13.5 crore vs ₹0.54 crore (YoY)
• EBITDA Margin: 14.34% vs 6.65% (YoY)

What's Changed

• EBITDA margin improved by 769 bps YoY, indicating better cost control and capacity utilization.
• Consolidated Net Profit rose from a low base of ₹0.54 crore to ₹13.5 crore, a 2,400% increase.
• Revenue growth of 58% YoY reflects higher volumes in the animal health API business.

Key Takeaways

• Operating leverage is playing out as revenue scale-up leads to disproportionate profit growth.
• The significant margin expansion suggests a stabilizing raw material environment and higher realization products.
• The company has successfully transitioned from a low-profitability base in the previous year to a more sustainable 14%+ margin profile.

SAHI Perspective

NGL Fine Chem’s Q4 performance is a clear signal of structural recovery. While the YoY growth percentages are inflated by a low base in Q4FY25, the sequential improvement in margins from mid-single digits to 14.3% is the real highlight. This suggests that the capacity expansions undertaken in recent quarters are now contributing meaningfully to the bottom line.

Market Implications

The strong earnings performance is likely to trigger a re-rating for the stock, which has been under pressure due to volatile API cycles. Positive impact is expected on the small-cap pharma sector, specifically companies focused on veterinary APIs. Capital allocation signals suggest continued focus on domestic manufacturing and export compliance.

Trading Signals

Market Bias: Bullish

Multi-fold PAT growth and 769 bps margin expansion confirm an operational turnaround, with revenue scaling to ₹150 crore providing a strong runway.

Overweight: Specialty Chemicals, API Manufacturing, Animal Health

Underweight: Import-dependent generic players

Trigger Factors:

• Sustainability of 14% EBITDA margins in Q1FY27
• Raw material cost trajectory for veterinary APIs
• Export volume growth to regulated markets

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian API and Specialty Chemical sector is witnessing a recovery as inventory destocking in global markets subsides. For veterinary API players like NGL, the demand remains inelastic, but competition from Chinese suppliers and raw material volatility remain key structural variables.

Key Risks to Watch

• Fluctuation in raw material prices impacting API spreads.
• Regulatory risks associated with USFDA or EU-GMP certifications for manufacturing units.
• High concentration in the animal health segment which can be seasonal.

Recent Developments

NGL Fine Chem recently announced the operationalization of its new manufacturing block at the Tarapur facility in April 2026, aimed at increasing capacity by 30%. The company also cleared an inspection for its Macura subsidiary, paving the way for higher-margin exports to Europe.

Closing Insight

NGL Fine Chem's return to double-digit margins and strong top-line growth positions it as a key turnaround candidate in the specialty pharma space for the upcoming fiscal year.

FAQs

What drove the 2,400% surge in NGL Fine Chem's profit?

The surge was primarily due to a low base effect from Q4FY25 (₹0.54 crore) combined with a 58% increase in revenue to ₹150 crore and a near-doubling of EBITDA margins to 14.34%.

Is the current 14.34% EBITDA margin sustainable?

Management's focus on higher-value veterinary APIs and improved capacity utilization suggests margins can stabilize between 13-15%, depending on raw material price stability.

How does this impact retail investors interested in the API sector?

Retail investors should note that while the YoY growth is massive, the company remains a small-cap entity where high volatility is common; the key metric to watch is consistent revenue growth above ₹140 crore per quarter.

High Performance Trading with SAHI.